drug-development
-
SURVEYOR opens the door for drugs that treat cognition
6 min read
Sage Therapeutics announced results from SURVEYOR, a trial that looked at cognitive changes in people with HD, and tested short-term safety of dalzanemdor. The study was small but met key goals, and additional trials are in progress.
By Dr Leora Fox -
A sprinkling of good news for the treatment of HD chorea
2 min read
A new form of the chorea drug valbenazine (INGREZZA) has been approved by the United States Food and Drug Administration (FDA) for those who have difficulty swallowing pills.
By Dr Leora Fox -
Huntington's Disease Therapeutics Conference 2024 – Day 2
13 min read
HDBuzz is back for Day 2 of the CHDI HD Therapeutics Conference: Wednesday February 28th in Palm Springs, California. This article summarizes our real-time updates of the conference in community-friendly language. Itās a brain disease This morningās session is titled āItās a brain diseaseā and will feature talks about BRAINSSSS! HD scientists are a bit…
-
Huntington's Disease Therapeutics Conference 2024 – Day 1
24 min read
Check out research updates from Day 1 of the 2024 HD Therapeutics Conference #HDTC2024
-
CRISPR-based drugs: one giant leap for mankind
10 min read
Casgevy is the first CRISPR-based drug to make its way through the approval process, all but curing Sickle Cell Disease and itās paving the way for similar drugs targeting other diseases. Is Huntingtonās disease next?
-
Putting it in print: GENERATION HD1 study results published
6 min read
Data from GENERATION HD1, the Phase 3 clinical trial testing the huntingtin-lowering drug tominersen, have just been published in a scientific journal. The trial ended a while back, so why is this an important milestone, and whatās next?
-
Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD
10 min read
The HD pipeline is rich and varied. Let's talk about some out-of-the-box approaches for developing drugs for HD that don't involve huntingtin lowering.
By Kelly Andrew -
Drug to treat movement symptoms of HD approved by FDA
6 min read
The FDA has approved valbenazine, also known as INGREZZA, as a treatment for the movement symptoms of Huntingtonās disease
-
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
8 min read
Novartis have announced that they are ending development of the drug branaplam in Huntingtonās disease. Here, we review this latest news and its impact on the HD community.
-
Artificial intelligence to save the day? How clever computers are helping us understand Huntingtonās disease.
5 min read
Scientists at IBM and the CHDI Foundation have used artificial intelligence to analyse datasets from Huntingtonās disease observational trials to model progression of the disease. They hope their findings will help improve clinical trial design.